Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This company does seem to be utterly useless / hopeless and it would be nice to think that it could be sold ASAP because the current lot of directors obviously haven't got a clue as to how to run a business. Anyone in agreement?
I guess shortfall is around 10%. FY to end Jan 23 was rev £41.2m, FY to end Jan 22 was £41.4m
Today FY to end Jan 24 is £37.0m
Agreed, ragnarlothbrok. It would have been so simple to state what the size of the shortfall is.
Awful…. Bad news, lack of clarity is striking. It’s going to sting today. I reckon back down to low 40s. Capital raising probably now required, heavily discounted of course
Not the best trading update...
Not seen any tips, they do have results due soon (released mid Feb last year) and given they submitted for Fda approval for the SLE6000 ventilator almost 6 months ago expecting an update on that fairly soon too. I think it was oversold and was overdue a rerate anyway
Hello, upward movement in the shares today suggests maybe a tip - any thoughts as too the source?
RNS out today - IHC buy Airon Corp for $2.5m ($1.5m from cash reserves and $1.0m to be paid at later date based on delivery of future revenues) Only a small outfit with revenue $1.4m, loss $0.4m, net assets $1.3m) however it will be a good platform to sell the SLE6000 neo natal ventillator, subject to FDA approval.
Looks a good acquisition to increase sales in large US market.
I've been buying a small amount of these over the last few days. It is very cheap but so is everything!!
On the plus side 0.5x sales is a huge discount to this type of company in the US. Cant see incidence of premature births being lower given issues around climate and pollution impacting pregnancy
On the negative side profitability is questionable, it was very healthy in 2022 but 2023 and this year looks the same. Lots of non recurring items, inflation pressures and a big chunk of profit goes on interest
The prospect of entering the US is interesting. They obviously have great products but the US is notoriously difficult to penetrate and competition looks pretty fierce
https://www.gminsights.com/industry-analysis/neonatal-ventilators-market#:~:text=Based%20on%20mobility%2C%20the%20neonatal,at%20over%20USD%20222.7%20million.
Is it possible that the only buyers of these shares are the directors and when they stop it might start its downward trend
The chart is truly horrendous, well below its all time low!
CFO buys 19577 shares at 35.5p.
Hopefully the Directors will tag team these buys and take share price back over 40p.
Still a daft price for such a solid business.
Decent sized Director buys - especially Chair who bought 100k shares at 32.95p
Bargain at these prices. Don't understand why anyone off loaded at below 30p, ludicrous decision, must be desperate for cash.
ShareSoc is holding its first hybrid event in London on 19th Oct! Hear from Inspiration Healthcare Group (IHC) and other healthcare companies like Tristel Plc (TSTL), Creo Medical Group (CREO), Abingdon Health (ABDX) and GENincode (GENI). 📍🌐 Attend in-person or online. Register: https://bit.ly/3FbyXfe
Obviously a larger selling off loading some shares - today the market makers walked the price down hard (10%) down to 30/28.5p on hardly any volume. Decent sized buys came in at 29-30p, but share price hardly lifted at all. After close market makers blended in, a 53,500 sell at 29p. These guys are always less than transparent and love their little games, don't they?..
Now the crazy thing is the business is worth just £20m now - down 80% off peak of 150p/share. Okay revenues have flatlined, margins tightened and company probably spent too much on tech centre - but worth only 20% of previous market cap??? Really??
They've also done some bold stuff, like reducing office space, headcount etc with the relocation / centralisation of business. Should pay off this year, now that's been done.
A bargain at 30p, but then there are so many ridiculously undervalued shares out there right now.
Got to be hostile takeover bid by PE at this price surely?
Further to my last post It would appear that an institutional investor is still selling - most likely some part of Premier Miton.
Is it 'The Diverse Income Trust' which was last reported as below 3% or some other part of Premier Miton? If neither then who?
Any thoughts please?
There does seem to be an institutional investor still reducing there holding that has been a drag on the shares.
Thanks Lesboy for reporting 'The Times' share tip - as not all shareholders read 'The Times' though from today's reaction clearly some shrewd investors do!
Is it co-incidence that the company is presenting a belated post results update this afternoon around 3pm on the 'Investor Meets Company' forum? - and an AGM later this month.
The Times share tip is handy in giving whoever is selling down IHC, plenty of liquidity to sell into.
Already 342,000 shares traded. Hopefully once the seller is out, IHC can move on upwards, just needs a couple of decent contract wins.
From today's Times:
Inspiration Healthcare’s share price chart would bring doctors running if it flashed up on monitors in the hospitals where its intensive care products are used. From 68p in 2020, the firm, which specialises in neonatal medical machines and aids, saw its stock more than double in the following 12 months before crashing back down to 84p over distribution issues in China last November and halving again to 45p now.
It’s either an ideal time to snap up a bargain in this Crawley-based medtech distributor — or it’s a dud that was overvalued in the Covid years, when its ventilators saw high demand from the NHS. Which is correct?
Inspiration was founded in 2003, and listed on Aim in 2015 via a reverse takeover of Inditherm, which specialises in technology that warms up very sick patients. Today, Inspiration’s key products include the all-in-one SLE6000 ventilator, non-invasive ventilators for babies and cerebral function monitoring systems; the firm sells its own UK-made products in 75 countries, generating 60 per cent of profits from overseas. Its neonatal market specialism is seeing growing demand: more than 15 million babies are born prematurely every year, but that figure is rising worldwide. The neonatal intensive care market is worth $6.8 billion and set to approach $10 billion by 2027, according to analysts ResearchandMarkets.com.
Yet Inspiration’s own trends have not reflected that opportunity. Results for the year to February were muted, with revenues almost flat at £41 million and underlying earnings falling from £6 million a year earlier to £4 million. Chief executive Neil Campbell said the firm had shown “resilience”, a barrel-scraper of a verdict.
There are reasons for cheer: Inspiration invested in a new manufacturing and technology centre in Croydon, increasing both its capacity and capability. It has reliable, high-quality customers, and revenues picked up in the fourth quarter of its last financial year, and amounted to almost £2 million cash in the first two months of its 2024 year. Its policy of investing about 9per cent of sales into R&D should gradually pay off.
Seb Jantet, analyst at house broker Liberum, is realistic: “the recent track record and poor cash generation warrant some caution,” he says, but names a punchy 100p target price because “Inspiration’s core offering is sound and … we expect the discount to peers to close.”
The price to earnings ratio is 9.6 for 2023, down from over 12 last year. Inspiration is a dicey investment, but its medical technology’s time has come: buy.
Were we supposed to get a trading update today? The rns about the investor day mentioned it would include a trading update, would they would not also have to also rns the update? Unless I've misunderstood the rns..
This share must be at the bottom now.....
You get everywhere mag lol. I don't care what they say, I quite like your posts!!!
This one looks good,
doing some more dd later
have plenty of orders
Just bought back in. Always liked this company. Gla.
Yeah I’m a master of the art form of understatement. A better description would be an absolute shocker of a RNS. I await the results with trepidation
Bit of an understatement that Herring!